Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild(University of Lübeck), Jean‐Jacques Grob(Assistance Publique Hôpitaux de Marseille), Lev Demidov(Russian Cancer Research Center NN Blokhin), Thomas Jouary(Hôpital Saint-André), Ralf Gutzmer(Medizinische Hochschule Hannover), Michael Millward(University of Western Australia), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Christian U. Blank(The Netherlands Cancer Institute), Wilson H. Miller(Jewish General Hospital), Eckhart Kaempgen(Comprehensive Cancer Center Erlangen), Salvador Martín‐Algarra(Clinica Universidad de Navarra), Bogusława Karaszewska, Cornelia Mauch(University Hospital Cologne), Vanna Chiarion‐Sileni(Istituto Oncologico Veneto), Anne-Marie Martin(GlaxoSmithKline (United States)), S. Swann(GlaxoSmithKline (United States)), Patricia Haney(GlaxoSmithKline (United States)), Beloo Mirakhur(GlaxoSmithKline (United States)), Mary Guckert(GlaxoSmithKline (United States)), Vicki Goodman(GlaxoSmithKline (United States)), Paul B. Chapman(Memorial Sloan Kettering Cancer Center)
Cited by 2,958